期刊
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
卷 35, 期 1, 页码 81-90出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COC.0b013e3181ec60b8
关键词
Yttrium-90; SIRT; metastases; chemoradiation; hepatic
类别
资金
- Sirtex Medical
Liver-directed therapies for unresectable cancers in the liver are evolving with increased efficacy and decreasing toxicity. One of these approaches uses radioactive microspheres delivered to hepatic tumors via the hepatic artery system-radioembolization. Use of this therapy is rapidly increasing worldwide with over 20,000 patients treated thus far. Therefore, greater understanding of its potential and optimal positioning of this therapy in the multimodality management of cancers affecting the liver is needed. This task has been undertaken by a group of the most experienced clinicians in radioembolization from multiple disciplines involved in this therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据